New glucose imaging could help personalize brain tumor treatment

NCT ID NCT06855628

Terminated Knowledge-focused Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new imaging technique called Deuterium Metabolic Imaging (DMI) to see if it can predict how well glioblastoma patients respond to treatment. Ten participants will drink a special glucose tracer before MRI scans. The goal is to improve treatment decisions, but the study is currently suspended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Deuterated glucose tracer (a special form of glucose used for imaging)
What this could lead to: If successful, this imaging technique could help doctors predict which glioblastoma treatments work best for each patient, leading to more personalized care.
What could go wrong: This is a very small, early-phase study with only 10 participants and is currently suspended. The imaging method may not reliably predict outcomes, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GBM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GBM GLIOMA

Contacts and locations

Locations

Stanford University

Palo Alto, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.